Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2005 September;57(3) > Minerva Urologica e Nefrologica 2005 September;57(3):141-9

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

REVIEWS  


Minerva Urologica e Nefrologica 2005 September;57(3):141-9

language: English

Immunosuppresive treatment options in renal transplantation

Ciancio G., Burke G. W., Jorge D., Rosen A., Miller J.

Department of Surgery Division of Transplantation University of Miami School of Medicine Miami, FL, USA


PDF  


An overview of the first 4 decades of clinical kidney transplantation would characterize progress primarily in the development of new immunosuppressive agents designed to reduce the incidence and severity of acute rejection to improve short-term outcomes, but with less marked effects on long-term patient and graft survival. The new trend of immunosuppressive therapy is to facilitate long-term allograft and patient survival, and to help to maintain a good quality of life after renal transplantation. To achieve these goals, transplant physicians need to determine the immunosuppressive protocols that will best minimize risk factors associated with reduced allograft/patient survival and quality of life. Recent protocols and clinical experience with modern immunosuppression strategies, as well as the efficacy and safety of various combination protocols, will be reviewed.

top of page

Publication History

Cite this article as

Corresponding author e-mail